Nuveen’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-304,125
| Closed | -$40.1M | – | 3463 |
|
|
2025
Q1 | $40.1M | Sell |
304,125
-215,128
| -41% | -$26.8M | 0.01% | 728 |
|
|
2024
Q4 | $43.4M | Buy |
519,253
+31,331
| +6% | +$2.57M | 0.01% | 711 |
|
|
2024
Q3 | $35.7M | Sell |
487,922
-79,902
| -14% | -$6.01M | 0.01% | 838 |
|
|
2024
Q2 | $38.9M | Sell |
567,824
-251,851
| -31% | -$17.5M | 0.01% | 746 |
|
|
2024
Q1 | $56.7M | Sell |
819,675
-61,356
| -7% | -$4.22M | 0.02% | 588 |
|
|
2023
Q4 | $63.1M | Buy |
881,031
+167,770
| +24% | +$9.65M | 0.02% | 520 |
|
|
2023
Q3 | $37.2M | Sell |
713,261
-246,679
| -26% | -$14.4M | 0.01% | 694 |
|
|
2023
Q2 | $60.8M | Buy |
959,940
+171,276
| +22% | +$10.7M | 0.02% | 514 |
|
|
2023
Q1 | $42.7M | Buy |
788,664
+52,016
| +7% | +$2.51M | 0.02% | 616 |
|
|
2022
Q4 | $39M | Buy |
736,648
+177,924
| +32% | +$8.92M | 0.02% | 639 |
|
|
2022
Q3 | $26M | Sell |
558,724
-79,874
| -13% | -$4.17M | 0.01% | 853 |
|
|
2022
Q2 | $36.5M | Sell |
638,598
-119,262
| -16% | -$6.76M | 0.01% | 686 |
|
|
2022
Q1 | $44.4M | Buy |
757,860
+123,973
| +20% | +$6.44M | 0.01% | 691 |
|
|
2021
Q4 | $22.2M | Sell |
633,887
-6,932
| -1% | -$291K | 0.01% | 1157 |
|
|
2021
Q3 | $23.9M | Sell |
640,819
-53,939
| -8% | -$1.88M | 0.01% | 1150 |
|
|
2021
Q2 | $28.4M | Sell |
694,758
-67,000
| -9% | -$2.48M | 0.01% | 1102 |
|
|
2021
Q1 | $25.8M | Sell |
761,758
-16,561
| -2% | -$575K | 0.01% | 1131 |
|
|
2020
Q4 | $24.8M | Sell |
778,319
-12,717
| -2% | -$334K | 0.01% | 1110 |
|
|
2020
Q3 | $20.3M | Buy |
791,036
+104,018
| +15% | +$2.37M | 0.01% | 1054 |
|
|
2020
Q2 | $17.6M | Buy |
687,018
+107,525
| +19% | +$2.18M | 0.01% | 1125 |
|
|
2020
Q1 | $8.91M | Buy |
579,493
+236,929
| +69% | +$5.15M | ﹤0.01% | 1359 |
|
|
2019
Q4 | $11.8M | Buy |
342,564
+100,953
| +42% | +$1.21M | ﹤0.01% | 1493 |
|
|
2019
Q3 | $1.8M | Sell |
241,611
-376,643
| -61% | -$3.61M | ﹤0.01% | 2447 |
|
|
2019
Q2 | $8.02M | Buy |
+618,254
| New | +$7.93M | ﹤0.01% | 1742 |
|
|
2016
Q3 | – | Sell |
-32,726
| Closed | -$1.27M | – | 1443 |
|
|
2016
Q2 | $1.27M | Buy |
32,726
+13,928
| +74% | +$500K | 0.01% | 931 |
|
|
2016
Q1 | $523 | Buy |
18,798
+4,211
| +29% | +$140K | ﹤0.01% | 1208 |
|
|
2015
Q4 | $785 | Sell |
14,587
-2,102
| -13% | -$106K | ﹤0.01% | 1156 |
|
|
2015
Q3 | $668 | Buy |
+16,689
| New | +$544K | ﹤0.01% | 1238 |
|
Other funds holding ITCI
KIM
HNB
Nuveen's ITCI Position: Q2 2025 in Review
Nuveen sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 304,125 shares — an estimated $40.1M sold.
Nuveen first reported a position in ITCI in Q3 2015 and held it in 28 quarters. The position peaked at $63.1M in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Nuveen reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Nuveen sold 304,125 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $40.1M.
- Nuveen first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 28 quarters.
- Nuveen's Intra-Cellular Therapies Inc. position peaked at $63.1M in Q4 2023.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.